Intrathecal Gadolinium (Gadopentetate Dimeglumine) Enhanced Magnetic Resonance Myelography and Cisternography
- 1 March 2002
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Investigative Radiology
- Vol. 37 (3), 152-159
- https://doi.org/10.1097/00004424-200203000-00008
Abstract
This cooperative multicenter human study was designed to evaluate the safety, magnetic resonance (MR) imaging characteristics, and clinical response to a single gadolinium contrast agent: gadopentetate dimeglumine. Ninety-five patients (age range: 1 month to 78 years; sex: 50 males, 45 females) were included in this prospective study. The patients presented clinically with a variety of cranial or spinal signs and symptoms for which an intrathecal contrast myelogram or cisternogram was requested by clinical staff. Via lumbar puncture (20-25 g needle), 3 to 5 mL/ml of cerebrospinal fluid were withdrawn and mixed with a single volume of 0.5 (n = 63), 0.7 (n = 13), 0.8 (n = 12), or 1.0 (n = 7) cc/mL of gadopentetate dimeglumine (Magnevist; Schering, Berlin, Germany). This was then injected into the subarachnoid space, and the needle was removed. Immediate and delayed (up to 96 hours) T1- and T2-weighted MR imaging was performed on super conductive, high-field (1.0-1.5 tesla) imaging units in two or three planes. All patients were hospitalized for an observation period of 24 hours following the procedure, and follow-up neurologic examinations were performed serially for 6 to 12 months afterward. No patient manifested gross behavioral changes, neurologic alterations, or seizure activity at any time following the procedure. Nineteen patients (20%) experienced postural postlumbar puncture headache, six patients had nausea (6%), and two patients had episodes of vomiting (2%), all which resolved within the first 24 hours of the lumbar puncture with conservative bed rest. This cooperative study demonstrates the general safety and feasibility of low dose (0.5-1.0 mL/ml) intrathecal gadopentetate dimeglumine administration. The potential useful clinical applications include the evaluation of obstructions and communications of the various subarachnoid spaces, spontaneous or traumatic/postsurgical craniospinal cerebrospinal fluid leaks, and subarachnoid space CSF flow and parenchymal CNS interstitial diffusion dynamics. This worldwide cooperative study seeks to progressively perform human studies for further definitive evaluation of the practical clinical applications, of the relationship of this technique to other imaging studies and modalities, and the long-term safety of the procedure in a larger number of subjects.Keywords
This publication has 13 references indexed in Scilit:
- Acute and Subacute Physiological and Histological Studies of the Central Nervous System After Intrathecal Gadolinium Injection in the Anesthetized RatInvestigative Radiology, 2001
- Evaluation of Gadopentetate Dimeglumine Magnetic Resonance Cisternography in an Animal ModelInvestigative Radiology, 1999
- Is it dangerous to inject MR contrast media into the subarachnoid space?Acta Radiologica, 1998
- Magnetic resonance ventriculography with gadolinium DTPA: report of two casesNeuroradiology, 1997
- Magnetic Resonance Imaging Contrast Media in the Subarachnoid SpaceInvestigative Radiology, 1997
- Anaphylactic shock induced by intravenous gadopentetate dimeglumineThe Lancet, 1992
- Safety of gadolinium‐DTPA: Extended clinical experienceMagnetic Resonance in Medicine, 1991
- Safety and Tolerance after Intravenous Administration of 0.3 mmol/kg Gd-DTPA: Results of a Randomized, Controlled Clinical TrialInvestigative Radiology, 1991
- Safety assessment of gadopentetate dimeglumine in U.S. clinical trials.Radiology, 1990
- MR cisternography and myelography with Gd-DTPA in monkeys.Radiology, 1985